{"name":"Deutsches Herzzentrum Muenchen","slug":"deutsches-herzzentrum-muenchen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"ORSIRO","genericName":"ORSIRO","slug":"orsiro","indication":"Other","status":"marketed"},{"name":"Abrupt Clopidogrel Interruption","genericName":"Abrupt Clopidogrel Interruption","slug":"abrupt-clopidogrel-interruption","indication":"Other","status":"marketed"},{"name":"Iomeprol 350","genericName":"Iomeprol 350","slug":"iomeprol-350","indication":"Other","status":"marketed"},{"name":"oral anticoagulation","genericName":"oral anticoagulation","slug":"oral-anticoagulation","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Clopidogrel Tapering","genericName":"Clopidogrel Tapering","slug":"clopidogrel-tapering","indication":"De-escalation strategy in acute coronary syndrome post-percutaneous coronary intervention","status":"marketed"},{"name":"Un-fractionated heparin","genericName":"Un-fractionated heparin","slug":"un-fractionated-heparin","indication":"Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)","status":"marketed"},{"name":"Abciximab + UFH","genericName":"Abciximab + UFH","slug":"abciximab-ufh","indication":"Acute coronary syndrome undergoing percutaneous coronary intervention","status":"marketed"}]}],"pipeline":[{"name":"Clopidogrel Tapering","genericName":"Clopidogrel Tapering","slug":"clopidogrel-tapering","phase":"marketed","mechanism":"Clopidogrel tapering is a dosing strategy that gradually reduces clopidogrel exposure after dual antiplatelet therapy to assess safety and efficacy of de-escalation in cardiovascular patients.","indications":["De-escalation strategy in acute coronary syndrome post-percutaneous coronary intervention","Assessment of dual antiplatelet therapy duration optimization"],"catalyst":""},{"name":"ORSIRO","genericName":"ORSIRO","slug":"orsiro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Un-fractionated heparin","genericName":"Un-fractionated heparin","slug":"un-fractionated-heparin","phase":"marketed","mechanism":"Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","indications":["Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)","Acute coronary syndrome","Atrial fibrillation for stroke prevention","Perioperative thromboprophylaxis","Extracorporeal circulation anticoagulation"],"catalyst":""},{"name":"Abciximab + UFH","genericName":"Abciximab + UFH","slug":"abciximab-ufh","phase":"marketed","mechanism":"Abciximab is a monoclonal antibody that blocks platelet glycoprotein IIb/IIIa receptors to prevent platelet aggregation, combined with unfractionated heparin (UFH) for anticoagulation during percutaneous coronary intervention.","indications":["Acute coronary syndrome undergoing percutaneous coronary intervention","Prevention of ischemic complications during coronary angioplasty"],"catalyst":""},{"name":"Abrupt Clopidogrel Interruption","genericName":"Abrupt Clopidogrel Interruption","slug":"abrupt-clopidogrel-interruption","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iomeprol 350","genericName":"Iomeprol 350","slug":"iomeprol-350","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"oral anticoagulation","genericName":"oral anticoagulation","slug":"oral-anticoagulation","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNdGcyemVKaVJnUG9ZZ0JKQ1QxZk40UmNrSG42R2NSaDZUeFBKd3g3YnJRWW5UckVKMkYxb0RWT2F4OFBzSHdjS0owMmEtSFBKNkhsUWo3Tl84a1NlNFdSWXlLOWd2cHg4a3VVX0lIX1Q0X0steFF4enVVSTM3aGRjYkpKVXZ2XzVlNG4yRmFTQWc0VkNNQ1p2SGNKd3NkMmMwdDd6T3hMaGd0bGMxZXJfZ0tWOFluWlNDZDNyeUJpejQ?oc=5","date":"2023-10-27","type":"pipeline","source":"Healio","summary":"Revascularization after treatment of in-stent restenosis high after 10 years - Healio","headline":"Revascularization after treatment of in-stent restenosis high after 10 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBNOS1LTzJnbWphTVBDV2ZfQ2JHd2k2dFBNMkFlc2tSSktLWHFMb0tzenNodVhwcTNKc2NjY2tHbHhTTHA1VGhQQXJ0VS1DM1pfWkt6QkJjSXRrT3oyX2J0dEg1MEs3Y3owQ3c?oc=5","date":"2021-11-18","type":"trial","source":"Wiley Online Library","summary":"A prospective trial of a novel low‐dose paclitaxel‐coated balloon therapy in patients with restenosis in drug‐eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatm","headline":"A prospective trial of a novel low‐dose paclitaxel‐coated balloon therapy in patients with restenosis in drug‐eluting co","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5haFVBMEdEQ3VlNC1IcWtrRlhoYWFjamZnSXA0RW5Cd0tPejljcEMwaGJIaVBMZ2NYb29jR0hxcGRWYTIwbTgtQTVERkdvQUNfdjE0OThWd2hEYmlqMWRtbw?oc=5","date":"2019-09-01","type":"pipeline","source":"NEJM","summary":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes - NEJM","headline":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":7},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}